{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"5050","value":"0.0"},{"groupId":"OG001","lowerLimit":"0","upperLimit":"4580","value":"0.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"20"}],"units":"Participants"}],"title":"CYCLE 1 DAY 1, PRE-DOSE"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"36700","value":"17000.0"},{"groupId":"OG001","lowerLimit":"7000","upperLimit":"81500","value":"45150.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"36"}],"units":"Participants"}],"title":"CYCLE 1 DAY 1, END OF INFUSION"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"9690","upperLimit":"41100","value":"17000.0"},{"groupId":"OG001","lowerLimit":"29800","upperLimit":"75900","value":"46800.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"32"},{"groupId":"OG001","value":"36"}],"units":"Participants"}],"title":"CYCLE 1 DAY 1, 2 HOURS"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4060","upperLimit":"27500","value":"12050.0"},{"groupId":"OG001","lowerLimit":"17100","upperLimit":"73100","value":"36200.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"34"}],"units":"Participants"}],"title":"CYCLE 1 DAY 1, 24 HOURS"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"750","upperLimit":"22500","value":"8005.0"},{"groupId":"OG001","lowerLimit":"9900","upperLimit":"39000","value":"22050.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"32"},{"groupId":"OG001","value":"36"}],"units":"Participants"}],"title":"CYCLE 1 DAY 4, ANYTIME SAMPLE"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"14000","value":"3970.0"},{"groupId":"OG001","lowerLimit":"5590","upperLimit":"30600","value":"15150.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"29"},{"groupId":"OG001","value":"36"}],"units":"Participants"}],"title":"CYCLE 1 DAY 8, ANYTIME SAMPLE"},{"categories":[{"measurements":[{"groupId":"OG001","lowerLimit":"4670","upperLimit":"13800","value":"10630.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"6"}],"units":"Participants"}],"title":"CYCLE 1 DAY 22, ANYTIME SAMPLE"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"16700","value":"1760.0"},{"groupId":"OG001","lowerLimit":"0","upperLimit":"25900","value":"5460.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"29"}],"units":"Participants"}],"title":"CYCLE 2 DAY 1, PRE-DOSE"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"38100","value":"21600.0"},{"groupId":"OG001","lowerLimit":"16500","upperLimit":"93000","value":"48400.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"31"}],"units":"Participants"}],"title":"CYCLE 2 DAY 1, END OF INFUSION"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"15700","value":"1935.0"},{"groupId":"OG001","lowerLimit":"1080","upperLimit":"26600","value":"8090.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"17"}],"units":"Participants"}],"title":"CYCLE 4 DAY 1, PRE-DOSE"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"7070","upperLimit":"61500","value":"20050.0"},{"groupId":"OG001","lowerLimit":"22100","upperLimit":"196000","value":"46250.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"16"}],"units":"Participants"}],"title":"CYCLE 4 DAY 1, END OF INFUSION"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"8320","value":"1110.0"},{"groupId":"OG001","lowerLimit":"629","upperLimit":"44500","value":"3680.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"14"}],"units":"Participants"}],"title":"CYCLE 6 DAY 1, PRE-DOSE"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"9470","upperLimit":"32500","value":"20200.0"},{"groupId":"OG001","lowerLimit":"2490","upperLimit":"77300","value":"37100.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"14"}],"units":"Participants"}],"title":"CYCLE 6 DAY 1, END OF INFUSION"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3800","upperLimit":"13300","value":"6550.0"},{"groupId":"OG001","lowerLimit":"1060","upperLimit":"60400","value":"9030.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"9"}],"units":"Participants"}],"title":"CYCLE 9 DAY 1, PRE-DOSE"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"16600","upperLimit":"37100","value":"29350.0"},{"groupId":"OG001","lowerLimit":"14900","upperLimit":"66300","value":"29600.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"9"}],"units":"Participants"}],"title":"CYCLE 9 DAY 1, END OF INFUSION"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1550","upperLimit":"16600","value":"7910.0"},{"groupId":"OG001","lowerLimit":"723","upperLimit":"17700","value":"6915.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"8"}],"units":"Participants"}],"title":"CYCLE 12 DAY 1, PRE-DOSE"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"10500","upperLimit":"38700","value":"33700.0"},{"groupId":"OG001","lowerLimit":"15100","upperLimit":"47600","value":"27950.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"8"}],"units":"Participants"}],"title":"CYCLE 12 DAY 1, END OF INFUSION"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4090","upperLimit":"8820","value":"6165.0"},{"groupId":"OG001","lowerLimit":"914","upperLimit":"42500","value":"6760.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"5"}],"units":"Participants"}],"title":"CYCLE 18 DAY 1, PRE-DOSE"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"16200","value":"2570.0"},{"groupId":"OG001","lowerLimit":"1180","upperLimit":"22100","value":"4050.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"20"}],"units":"Participants"}],"title":"END OF TREATMENT (~157 weeks)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"37"}],"units":"Participants"}],"description":"Blood samples were collected for PK analysis of Belantamab mafodotin total antibody.","dispersionType":"Full Range","groups":[{"description":"In CE Phase, Participants with RRMM received 0.95 mg/ kg belantamab mafodotin IV infusion as powder for solution once every 3 weeks (Q3W), infused over 30- 60 minutes on day 1 of 21-day cycles in combination with 100 mg nirogacestat BID on day 1, 4, 8 and 15 of 21-day cycles. Treatment was administered until disease progression, intolerable toxicity, informed consent withdrawal, the end of the sub-study or death.","id":"OG000","title":"CE Phase: 0.95mg/kg Belantamab Mafodotin Q3W + Nirogacestat"},{"description":"In CE Phase, Participants with RRMM received 2.5 mg/ kg belantamab mafodotin IV infusion as powder for solution Q3W, infused over 30- 60 minutes on day 1 of 21-day cycles until disease progression, intolerable toxicity, informed consent withdrawal, the end of the sub-study or death.","id":"OG001","title":"CE Phase: 2.5mg/kg Belantamab Mafodotin Q3W"}],"paramType":"MEDIAN","populationDescription":"Pharmacokinetic population. Only those participants who were measured and analyzed (i.e., contributed data reported in the table) were included in the Overall Number of Participants Analyzed field. 'Number Analyzed' signifies participants evaluable for the specified timepoints. The \"0\" participants analyzed represents that data was not collected or available for analysis at that particular time point for the respective Arms/Groups.","reportingStatus":"POSTED","timeFrame":"PRE-DOSE(PD), END OF INFUSION (EOI), EOI+2 HOURS(H), EOI+ 24H on Day(D) 1 of Cycle (C) 1; ANYTIME on C1 D4, D8, and D22; PD and EOI on D1 of C2, C4, C6, C9, C12; PD on D1 of C18; End of Treatment (appoximately 157 weeks)","title":"CE Phase: Plasma Concentration of Belantamab Mafodotin Plasma Total Antibody","type":"SECONDARY","unitOfMeasure":"ng/mL"}